Post-transplant Lymphoproliferative Syndrome in the Pediatric Liver Transplant Population

Ernesto P. Molmenti, David E. Nagata, Jay S. Roden, Robert H. Squires, Hebe Molmenti, Carlos G. Fasola, Naomi Winick, Gail Tomlinson, M. James Lopez, Lisa D'Amico, Heather L. Dyer, Adria C. Savino, Edmund Q. Sanchez, Marlon F. Levy, Robert M. Goldstein, John A. Andersen, Goran B. Klintmalm

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Post-transplant lymphoproliferative disease remains a complication with a high morbidity and mortality. The present study examined 291 pediatric liver transplants performed in 263 children from October 1984 to December 1999. Post-transplant lymphoproliferatfve disease has an overall incidence of 12%. Tacrolimus and cyclosporine had a similar incidence of post-transplant lymphoproliferative disease. Fifty-six per cent of patients who developed post-transplant lymphoproliferative disease were Epstein-Barr virus negative at the time of transplantation. Mean time of conversion to Epstein-Barr virus positivity was 1.1 years after liver transplantation. Ten per cent of those who developed post-transplant lymphoproliferative disease never had Epstein-Barr virus detected. Mean time from Epstein-Barr virus positivity to detection of post-transplant lymphoproliferative disease was 2.68 years, and 3.13 years from liver transplantation (OLTx) to post-transplant lymphoproliferative disease. There was a 35% incidence of mortality. Deaths occurred a mean of 0.76 years after diagnosis of post-transplant lymphoproliferative disease. Most cases of post-transplant lymphoproliferative disease had extranodal location. There was one recurrence in 10% of patients, and two in 3%. All recurrent cases were seen in recipients who became Epstein-Barr virus positive after transplantation. There has been a decrease in the incidence of post-transplant lymphoproliferative disease from 15% to 9% to 4%. Post-transplant lymphoproliferative disease should be diagnosed promptly and treated aggressively. The best treatment, however, seems to be prevention, starting in the immediate postoperative period. Survivors should be monitored for both recurrence of post-transplant lymphoproliferative disease and acute cellular rejection.

Original languageEnglish (US)
Pages (from-to)356-359
Number of pages4
JournalAmerican Journal of Transplantation
Volume1
Issue number4
DOIs
StatePublished - Nov 2001

Fingerprint

Pediatrics
Transplants
Liver
Population
Human Herpesvirus 4
Incidence
Liver Transplantation
Transplantation
Recurrence
Mortality
Tacrolimus
Acute Disease
Postoperative Period
Cyclosporine
Survivors
Morbidity

Keywords

  • Epstein-Barr virus
  • Immunosuppression
  • Pediatric liver transplantation
  • Post-transplant lymphoproliferative disease
  • Post-transplant lymphoproliferative syndrome

ASJC Scopus subject areas

  • Immunology

Cite this

Molmenti, E. P., Nagata, D. E., Roden, J. S., Squires, R. H., Molmenti, H., Fasola, C. G., ... Klintmalm, G. B. (2001). Post-transplant Lymphoproliferative Syndrome in the Pediatric Liver Transplant Population. American Journal of Transplantation, 1(4), 356-359. https://doi.org/10.1034/j.1600-6143.2001.10411.x

Post-transplant Lymphoproliferative Syndrome in the Pediatric Liver Transplant Population. / Molmenti, Ernesto P.; Nagata, David E.; Roden, Jay S.; Squires, Robert H.; Molmenti, Hebe; Fasola, Carlos G.; Winick, Naomi; Tomlinson, Gail; Lopez, M. James; D'Amico, Lisa; Dyer, Heather L.; Savino, Adria C.; Sanchez, Edmund Q.; Levy, Marlon F.; Goldstein, Robert M.; Andersen, John A.; Klintmalm, Goran B.

In: American Journal of Transplantation, Vol. 1, No. 4, 11.2001, p. 356-359.

Research output: Contribution to journalArticle

Molmenti, EP, Nagata, DE, Roden, JS, Squires, RH, Molmenti, H, Fasola, CG, Winick, N, Tomlinson, G, Lopez, MJ, D'Amico, L, Dyer, HL, Savino, AC, Sanchez, EQ, Levy, MF, Goldstein, RM, Andersen, JA & Klintmalm, GB 2001, 'Post-transplant Lymphoproliferative Syndrome in the Pediatric Liver Transplant Population', American Journal of Transplantation, vol. 1, no. 4, pp. 356-359. https://doi.org/10.1034/j.1600-6143.2001.10411.x
Molmenti, Ernesto P. ; Nagata, David E. ; Roden, Jay S. ; Squires, Robert H. ; Molmenti, Hebe ; Fasola, Carlos G. ; Winick, Naomi ; Tomlinson, Gail ; Lopez, M. James ; D'Amico, Lisa ; Dyer, Heather L. ; Savino, Adria C. ; Sanchez, Edmund Q. ; Levy, Marlon F. ; Goldstein, Robert M. ; Andersen, John A. ; Klintmalm, Goran B. / Post-transplant Lymphoproliferative Syndrome in the Pediatric Liver Transplant Population. In: American Journal of Transplantation. 2001 ; Vol. 1, No. 4. pp. 356-359.
@article{1cd9d6a6880d4cba8b510d515ad9e36b,
title = "Post-transplant Lymphoproliferative Syndrome in the Pediatric Liver Transplant Population",
abstract = "Post-transplant lymphoproliferative disease remains a complication with a high morbidity and mortality. The present study examined 291 pediatric liver transplants performed in 263 children from October 1984 to December 1999. Post-transplant lymphoproliferatfve disease has an overall incidence of 12{\%}. Tacrolimus and cyclosporine had a similar incidence of post-transplant lymphoproliferative disease. Fifty-six per cent of patients who developed post-transplant lymphoproliferative disease were Epstein-Barr virus negative at the time of transplantation. Mean time of conversion to Epstein-Barr virus positivity was 1.1 years after liver transplantation. Ten per cent of those who developed post-transplant lymphoproliferative disease never had Epstein-Barr virus detected. Mean time from Epstein-Barr virus positivity to detection of post-transplant lymphoproliferative disease was 2.68 years, and 3.13 years from liver transplantation (OLTx) to post-transplant lymphoproliferative disease. There was a 35{\%} incidence of mortality. Deaths occurred a mean of 0.76 years after diagnosis of post-transplant lymphoproliferative disease. Most cases of post-transplant lymphoproliferative disease had extranodal location. There was one recurrence in 10{\%} of patients, and two in 3{\%}. All recurrent cases were seen in recipients who became Epstein-Barr virus positive after transplantation. There has been a decrease in the incidence of post-transplant lymphoproliferative disease from 15{\%} to 9{\%} to 4{\%}. Post-transplant lymphoproliferative disease should be diagnosed promptly and treated aggressively. The best treatment, however, seems to be prevention, starting in the immediate postoperative period. Survivors should be monitored for both recurrence of post-transplant lymphoproliferative disease and acute cellular rejection.",
keywords = "Epstein-Barr virus, Immunosuppression, Pediatric liver transplantation, Post-transplant lymphoproliferative disease, Post-transplant lymphoproliferative syndrome",
author = "Molmenti, {Ernesto P.} and Nagata, {David E.} and Roden, {Jay S.} and Squires, {Robert H.} and Hebe Molmenti and Fasola, {Carlos G.} and Naomi Winick and Gail Tomlinson and Lopez, {M. James} and Lisa D'Amico and Dyer, {Heather L.} and Savino, {Adria C.} and Sanchez, {Edmund Q.} and Levy, {Marlon F.} and Goldstein, {Robert M.} and Andersen, {John A.} and Klintmalm, {Goran B.}",
year = "2001",
month = "11",
doi = "10.1034/j.1600-6143.2001.10411.x",
language = "English (US)",
volume = "1",
pages = "356--359",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Post-transplant Lymphoproliferative Syndrome in the Pediatric Liver Transplant Population

AU - Molmenti, Ernesto P.

AU - Nagata, David E.

AU - Roden, Jay S.

AU - Squires, Robert H.

AU - Molmenti, Hebe

AU - Fasola, Carlos G.

AU - Winick, Naomi

AU - Tomlinson, Gail

AU - Lopez, M. James

AU - D'Amico, Lisa

AU - Dyer, Heather L.

AU - Savino, Adria C.

AU - Sanchez, Edmund Q.

AU - Levy, Marlon F.

AU - Goldstein, Robert M.

AU - Andersen, John A.

AU - Klintmalm, Goran B.

PY - 2001/11

Y1 - 2001/11

N2 - Post-transplant lymphoproliferative disease remains a complication with a high morbidity and mortality. The present study examined 291 pediatric liver transplants performed in 263 children from October 1984 to December 1999. Post-transplant lymphoproliferatfve disease has an overall incidence of 12%. Tacrolimus and cyclosporine had a similar incidence of post-transplant lymphoproliferative disease. Fifty-six per cent of patients who developed post-transplant lymphoproliferative disease were Epstein-Barr virus negative at the time of transplantation. Mean time of conversion to Epstein-Barr virus positivity was 1.1 years after liver transplantation. Ten per cent of those who developed post-transplant lymphoproliferative disease never had Epstein-Barr virus detected. Mean time from Epstein-Barr virus positivity to detection of post-transplant lymphoproliferative disease was 2.68 years, and 3.13 years from liver transplantation (OLTx) to post-transplant lymphoproliferative disease. There was a 35% incidence of mortality. Deaths occurred a mean of 0.76 years after diagnosis of post-transplant lymphoproliferative disease. Most cases of post-transplant lymphoproliferative disease had extranodal location. There was one recurrence in 10% of patients, and two in 3%. All recurrent cases were seen in recipients who became Epstein-Barr virus positive after transplantation. There has been a decrease in the incidence of post-transplant lymphoproliferative disease from 15% to 9% to 4%. Post-transplant lymphoproliferative disease should be diagnosed promptly and treated aggressively. The best treatment, however, seems to be prevention, starting in the immediate postoperative period. Survivors should be monitored for both recurrence of post-transplant lymphoproliferative disease and acute cellular rejection.

AB - Post-transplant lymphoproliferative disease remains a complication with a high morbidity and mortality. The present study examined 291 pediatric liver transplants performed in 263 children from October 1984 to December 1999. Post-transplant lymphoproliferatfve disease has an overall incidence of 12%. Tacrolimus and cyclosporine had a similar incidence of post-transplant lymphoproliferative disease. Fifty-six per cent of patients who developed post-transplant lymphoproliferative disease were Epstein-Barr virus negative at the time of transplantation. Mean time of conversion to Epstein-Barr virus positivity was 1.1 years after liver transplantation. Ten per cent of those who developed post-transplant lymphoproliferative disease never had Epstein-Barr virus detected. Mean time from Epstein-Barr virus positivity to detection of post-transplant lymphoproliferative disease was 2.68 years, and 3.13 years from liver transplantation (OLTx) to post-transplant lymphoproliferative disease. There was a 35% incidence of mortality. Deaths occurred a mean of 0.76 years after diagnosis of post-transplant lymphoproliferative disease. Most cases of post-transplant lymphoproliferative disease had extranodal location. There was one recurrence in 10% of patients, and two in 3%. All recurrent cases were seen in recipients who became Epstein-Barr virus positive after transplantation. There has been a decrease in the incidence of post-transplant lymphoproliferative disease from 15% to 9% to 4%. Post-transplant lymphoproliferative disease should be diagnosed promptly and treated aggressively. The best treatment, however, seems to be prevention, starting in the immediate postoperative period. Survivors should be monitored for both recurrence of post-transplant lymphoproliferative disease and acute cellular rejection.

KW - Epstein-Barr virus

KW - Immunosuppression

KW - Pediatric liver transplantation

KW - Post-transplant lymphoproliferative disease

KW - Post-transplant lymphoproliferative syndrome

UR - http://www.scopus.com/inward/record.url?scp=0345144355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345144355&partnerID=8YFLogxK

U2 - 10.1034/j.1600-6143.2001.10411.x

DO - 10.1034/j.1600-6143.2001.10411.x

M3 - Article

C2 - 12099380

AN - SCOPUS:0345144355

VL - 1

SP - 356

EP - 359

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 4

ER -